Company intelligence / Profile preview

MedLumics

Ownership: Private
Development stage: Phase 1

Overview

MedLumics has developed AblaView®, an investigational optically guided real-time catheter ablation system for atrial fibrillation. The company achieved pre-clinical feasibility in 2020 and is preparing for first-in-human regulatory clinical studies. No commercial or late-stage clinical results have been published yet.

Therapeutic areas: Cardiovascular
Modalities: DeviceCatheter-based systemRadio-frequency ablation systemIrreversible electroporation ablation system
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

AblaView

Phase 1

Indications: Atrial fibrillation

Partnerships

No major pharmaceutical or biotech partnerships disclosed; investors include public and private funds such as CDTI Innvierte Economía and VI Partners Swiss Innovation Fund

Beyond the preview

Go deeper on MedLumics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedLumics.

Explore the full profile